Vial Guide
PreclinicalCNTF-derived neurotrophic peptide (experimental)

P21

P021, P-21, Peptide 021, Ac-DGGL-adamantylglycine-NH2

Common dose
No tested dose
Cycle
No set cycle
Vial sizes
Not established

A small synthetic peptide made from four amino acids of ciliary neurotrophic factor (CNTF), a protein that keeps nerve cells alive, capped with a bulky adamantane group so it resists breakdown and reaches the brain. In mice and rats it raised BDNF, a brain growth signal, and the birth of new nerve cells in the hippocampus, the brain’s memory center.

Evidence. Cell and animal data only, nearly all from the New York lab that designed it in 2010. Given in food for months, it improved memory and reduced tau changes in Alzheimer’s-model mice and in old rats. No one has been given it in a published study and no trial is registered (ClinicalTrials.gov, October 2026); a company co-founded by its inventor holds the development license.

What it’s used for

None of these uses is approved, and none has been tested in people. Here is what each claim rests on.

Alzheimer’s disease
AnimalUnproven in people: in Alzheimer’s-model mice, months of P21 in food reduced tau buildup, lowered soluble amyloid-β and improved memory. It has never been tested in anyone with Alzheimer’s.
Memory decline with aging
AnimalUnproven: in 22–24-month-old rats, P21 by mouth eased age-related learning and memory decline, restored new nerve-cell growth and lowered tau in spinal fluid. No human data.
Memory and focus in healthy adults
AnimalUnproven: healthy adult mice given P21 did better on learning and memory tests in its 2010 debut study. No study has tested it in healthy people.
Down syndrome
AnimalUnproven: given to pregnant and nursing mice of a Down syndrome model, it prevented developmental delay in the pups and memory problems in adulthood. Never tested in people.
Age-related macular degeneration
AnimalUnproven: in old rats treated for 3 months and Alzheimer’s-model mice treated for 18 months, it reduced retinal changes resembling macular degeneration. No human data.

Animal: cell or animal studies only.

Every compound’s uses, by body system: evidence map, and by condition: conditions A to Z.

Status

Approval
Not approved as a drug in the US, the EU or anywhere else. No human trial has been registered; Phanes Biotech, co-founded by the peptide’s inventor, holds a worldwide license to develop it.
US compounding
Never nominated for pharmacy compounding, so it appears on none of FDA’s 503A or 503B bulk substance category lists (503A list updated May 14, 2026).
European Union
No marketing authorization; no P21 product is approved anywhere, and it has never been tested in people.
United Kingdom
No marketing authorization (MHRA).
Canada
No marketing authorization (Health Canada).
Australia
No marketing authorization. P21 isn’t named in the Poisons Standard (October 2026).
Sport (WADA 2026)
Likely banned in sportNot named in the 2026 List. An unapproved compound still in preclinical development falls under S0 non-approved substances, banned at all times. As a growth factor mimic it could also be read as an S2.3 growth factor modulator, likewise banned at all times.

Category 2 is FDA’s list of bulk substances that may present significant safety risks in compounding. The 503A bulks list adds substances that pharmacies may compound with. Advisory committee votes are advice; FDA makes the final decision. Sport status follows the WADA Prohibited List in force since January 1, 2026; athletes should confirm with their anti-doping organization. Checked October 5, 2026. Status outside the US checked October 7, 2026 against EMA, MHRA, Health Canada and TGA records. By country: EU, UK, Canada, Australia. Status of every compound.

How it works

P21 copies the part of ciliary neurotrophic factor (CNTF), a protein that keeps nerve cells alive, that its inventors mapped as the active site. In mice and rats it raised BDNF, a growth signal for brain cells, and damped leukemia inhibitory factor, a signal that holds back new nerve cells. More new neurons survived in the hippocampus, and lower activity of GSK-3β, an enzyme that adds phosphate to tau, the protein that clumps in Alzheimer’s, went with less tau buildup.

AnimalMainly from cell and animal studies; not shown in people.

Not known

Its direct target on cells hasn’t been identified. The developers report that it enters the brain in rats, but whether it reaches the human brain, or changes anything there, has never been tested.

Protocol

Community

No dose has been tested in any person. Public guides quote anything from 100 mcg to 2 mg a day, disagree by twentyfold, and none of them cites a study of P21 in people.

Frequency
Not established
Route
Subcutaneous injection or nasal spray (community). The animal studies mostly gave it by mouth, mixed into food.
Cycle
No established cycle. Reports mention 4–8 weeks, with nothing behind the figure.

No set cycle, shown over 26 weeks

Common protocols

The ways P21 is most often run, each tagged with where it comes from.

Community injection

Community
Dose
No tested dose; guides disagree by twentyfold
How often
Usually described as once daily
How long
Reports mention 4–8 weeks

Not tested in any study. The amounts quoted online trace back to sellers and user reports, not to animal or human data.

Community nasal spray

Community
Dose
No tested dose; strength per spray isn’t standardized
How often
Usually described as once daily
How long
Reports mention 4–6 weeks

Several guides mention nasal use. No study has given P21 to a person by any route.

Taking it

Where it goes

Community use is injection under the skin with rotating sites, or a nasal spray. The animal studies mostly mixed it into food; no study has tested injection or nasal use in people.

If you miss a dose

No published guidance. Skip the missed dose and take the next one on schedule; don’t double up.

Missed doses for every compound

What to expect

  1. In healthy adult mice

    Learning and short-term and spatial memory improved, with more new nerve cells maturing in the hippocampus (Li 2010).

    Animal
  2. After months in food, old rats

    In 22–24-month-old rats it reduced the age-related decline in learning and memory, restored new nerve-cell growth and raised BDNF (Bolognin 2014).

    Animal
  3. 12 months in food, Alzheimer’s-model mice

    Less abnormal tau, lower soluble amyloid-β and better memory than untreated model mice, with treatment started at 9–10 months of age (Kazim 2014).

    Animal
  4. In people

    Nothing is known. It is sold for memory, focus and brain aging, but no study has tested it in anyone.

    Community

Side effects and what to do

Unknown in people

No one has been given P21 in a published study, so its side effects and their rates are unknown.

Trouble sleeping or feeling overstimulated (user reports)

Mentioned in a public guide; no study has looked. Users move the dose earlier in the day or stop.

Loss of appetite, nausea and weight loss (seen with the full CNTF protein in people)

Not seen in mice given P21 for months. Track weight and appetite, and stop if they change.

Injection-site pain, redness or infection (unregulated vials)

Use sterile technique. Spreading redness, heat or pus needs medical care.

Stop and get medical help

Hives, swelling of the face or throat, or trouble breathing after a dose: stop and get medical help. A hot, spreading red injection site with fever needs urgent care.

Can it cause …?

The side effects people ask about most, answered one by one. Each answer says where it comes from.

Nausea or vomiting
No dataNo human data for P21. Its parent protein, CNTF, caused dose-related nausea in a 570-patient ALS trial.
Trouble sleeping
CommunityTrouble sleeping or feeling overstimulated is the complaint user reports mention most. No study has looked.
Joint or muscle pain
AnimalNo human data. Full CNTF protein caused weakness in a large ALS trial, but mice given P21 showed no movement problems.
More hunger
AnimalNo human data. Full CNTF protein curbed appetite and caused weight loss in people, but mice given P21 for 120 days kept a normal body weight.
Cancer risk
PrecautionUnknown. It raises BDNF and the growth of new nerve cells, and no long-term study has looked at cancer risk, in animals or people.
TirednessHeadacheDiarrhea or constipationDizzinessHair lossAcne, rash or skin changesWater retention or swellingAnxiety, low mood or irritabilityLow or high blood sugarFast heartbeat or blood pressure changesLiver strainKidney problems
No dataNo human data: no one has been given P21 in a published study, so side effects are unknown.

Community: reported by users, not studied. Precaution: a concern that follows from how it works or from a related drug, not measured. Animal: seen only in animal studies. No data: no human safety data. A side effect that hasn’t been reported can still happen, especially with long or high-dose use. Any of these across every compound: the side-effect finder.

Who should avoid it

No product label covers P21, so these come from human studies and from precautions based on how it works. Most important first.

Pregnancy or breastfeeding
PrecautionNo human safety data exist. Mouse studies gave it through pregnancy and nursing to study the pups’ brains, not to test safety.
Anyone with active or past cancer
PrecautionIt boosts BDNF and the growth of new nerve cells. Growth signals like these haven’t been tested in anyone with cancer, and no long-term cancer study exists.
Anyone relying on product quality
PrecautionSold only as an unregulated research chemical, in vials and premixed sprays. Nothing checks that it contains the right molecule, at the stated amount, free of contamination.

Interactions

No interaction studies have been published, and no product label lists any.

Precaution: follows from how it works or from a related drug, and hasn’t been tested. This isn’t a complete list: a pharmacist or doctor can check a specific medicine or condition. Every documented interaction, by medicine: drug interactions.

Special situations

What’s known about pregnancy, breastfeeding, kidney and liver problems, age and surgery. Where nothing has been studied, the row says so.

Pregnancy
PrecautionNo human data. Mouse studies gave it through pregnancy to study the pups’ brain development, not to test safety, so effects on a human pregnancy are unknown.
Breastfeeding
PrecautionNo human data; it isn’t known whether it passes into breast milk.
Kidney problems
PrecautionNot studied in kidney disease, and how the body clears it hasn’t been published.
Liver problems
PrecautionNot studied in liver disease, and how the body breaks it down hasn’t been published.
Older adults
PrecautionNot studied in older people. The benefits were seen in old rats and aging Alzheimer’s-model mice; whether they carry over to people is unknown.
Children and teens
PrecautionNot studied in anyone under 18, and not approved for any age.
Surgery and anesthesia
PrecautionNo data; tell the surgical team about any injected compound.

Precaution: not studied, so the caution follows from how it works or from a related drug. Ages are given as approved or studied; this site never gives doses for children. Across every compound: pregnancy, breastfeeding, kidney disease, liver disease, older adults and surgery.

Tracking and pairing

Worth tracking

  • Body weight and appetite
  • Sleep
  • Injection sites

Often paired with

Usually run on its own.

Human studies

No published human studies of P21 turned up in our October 2026 review. The evidence note at the top of this page sums up what is known.

Trials under way

No ongoing trial of P21 is registered, and none has finished recently without publishing its results. Checked on ClinicalTrials.gov, October 7, 2026. Every compound: trials under way.

Limits of the evidence

Everything known comes from cells, mice and rats, nearly all from the New York lab that designed P21, whose leader co-founded the company licensed to develop it. The animals mostly ate it in food for months; injections and nasal sprays, the ways it is used online, haven’t been studied. No person has received it in a published study, so the dose, effects and safety in people are unknown.

How it’s supplied

No vial size or dose has been established for P21, so there’s no mixing math to show.

Sold as powder vials and premixed nasal sprays, both as unregulated research chemicals. Strengths vary between sellers and nothing checks them, so the amount in a vial or a spray is unknown. Vial Guide gives no mixing or dose figures for a compound no person has received in a published study.

Datasheet

Half-life
No reliable value has been published.
Type
Peptide, 5 amino acids
Molecular weight
578.7 g/mol
Formula
C27H42N6O8
Sequence
Ac-DGGL-(adamantylglycine)-NH2
Storage before use
Freezer (−20 °C) for long-term storage, kept dry and dark.
After mixing or opening
Fridge (2–8 °C) once in solution.
  • Molecule: PubChem CID 56599151 (CAS 1246751-68-7); FDA GSRS UNII VV8CZC8PAS (578.66). DGGL is residues 148–151 of human CNTF (UniProt P26441); the end unit is a 3-amino-adamantane-1-carboxamide group. Free peptide, not a salt
  • Storage: Community Common research-chemical practice; no approved label exists for this peptide

Every compound side by side: the half-life chart and the storage chart.

Identifiers

CAS number
1246751-68-7
UNII (FDA)
VV8CZC8PAS
ATC code
None assigned
Development codes
P021, P-21, Peptide 021
PubChem CID
56599151 (a second record, 56589645, “Peptide 021”, has the same formula and weight)
Brand names
None; no product is approved anywhere
First described
Described in 2010 by Khalid Iqbal’s lab, New York State Institute for Basic Research, Staten Island (Li et al.).

Every compound’s numbers: the identifiers table.

Product form and quality

Sold as P21 or P021 in powder vials and premixed nasal sprays. The published molecule is four amino acids plus an adamantane group, 578.7 g/mol; the cell-cycle protein p21 is unrelated. Nothing regulates identity, purity or sterility.

Cautions

  • Never given to a person in a published study, so there is no tested dose, schedule or safety record.
  • Its parent protein, CNTF, failed in a 570-patient trial in ALS and caused loss of appetite, weight loss and nausea, with more deaths at the top dose. P21 is far smaller and those effects weren’t seen in mice, but it hasn’t been tested in people.
  • Nearly all the research comes from the lab that invented it, and the inventor co-founded the company licensed to develop it.
  • “P21” is also the name of an unrelated cell-cycle protein, p21. Nothing checks what an unregulated vial or spray contains.

Questions

What is P21?

A small synthetic peptide made from four amino acids of ciliary neurotrophic factor (CNTF), a protein that keeps nerve cells alive, capped with a bulky adamantane group so it resists breakdown and reaches the brain. In mice and rats it raised BDNF, a brain growth signal, and the birth of new nerve cells in the hippocampus, the brain’s memory center.

How does P21 work?

P21 copies the part of ciliary neurotrophic factor (CNTF), a protein that keeps nerve cells alive, that its inventors mapped as the active site. In mice and rats it raised BDNF, a growth signal for brain cells, and damped leukemia inhibitory factor, a signal that holds back new nerve cells. More new neurons survived in the hippocampus, and lower activity of GSK-3β, an enzyme that adds phosphate to tau, the protein that clumps in Alzheimer’s, went with less tau buildup. Its direct target on cells hasn’t been identified. The developers report that it enters the brain in rats, but whether it reaches the human brain, or changes anything there, has never been tested.

Is P21 FDA-approved?

Not approved as a drug in the US, the EU or anywhere else. No human trial has been registered; Phanes Biotech, co-founded by the peptide’s inventor, holds a worldwide license to develop it. Never nominated for pharmacy compounding, so it appears on none of FDA’s 503A or 503B bulk substance category lists (503A list updated May 14, 2026).

What is the usual P21 dose?

From community reports, not established: No dose has been tested in any person. Public guides quote anything from 100 mcg to 2 mg a day, disagree by twentyfold, and none of them cites a study of P21 in people. These are the amounts sources reference, not recommendations.

Who should avoid P21?

No product label covers P21, so these come from human studies and from precautions based on how it works. Pregnancy or breastfeeding: No human safety data exist. Mouse studies gave it through pregnancy and nursing to study the pups’ brains, not to test safety. Anyone with active or past cancer: It boosts BDNF and the growth of new nerve cells. Growth signals like these haven’t been tested in anyone with cancer, and no long-term cancer study exists. Anyone relying on product quality: Sold only as an unregulated research chemical, in vials and premixed sprays. Nothing checks that it contains the right molecule, at the stated amount, free of contamination.

How should P21 be stored?

Before mixing: Freezer (−20 °C) for long-term storage, kept dry and dark. After mixing: Fridge (2–8 °C) once in solution. This is common practice; no product label covers it.

Is P21 banned in sport?

Probably. Not named in the 2026 List. An unapproved compound still in preclinical development falls under S0 non-approved substances, banned at all times. As a growth factor mimic it could also be read as an S2.3 growth factor modulator, likewise banned at all times.

Has P21 been studied in people?

No published human studies turned up in our October 2026 review. The evidence note at the top of this page sums up what is known.

How long has P21 been studied in people?

No data No human studies: no one has been given P21 in a published study, and no trial is registered.

Does P21 come in other forms, like a pill or nasal spray?

Animal Never given to people by any route. Animal studies mostly gave it by mouth, in food; injection under the skin and nasal sprays are community routes no study has tested.

Can you drink alcohol while taking P21?

No study No data. No study has looked at P21 and alcohol together.

Can P21 be taken with semaglutide or tirzepatide?

No study No study has combined them. No interaction is known, but none has been looked for.

What happens if you take too much P21?

No data There’s no label, no overdose data and no human dosing study. Call Poison Help (1-800-222-1222), or emergency services for severe symptoms.

Sources

  • Li et al., design of P21, an adamantane-capped CNTF peptide that improved memory and neurogenesis in mice (FEBS Lett 2010) PMID 20600002
  • Kazim et al., 12 months of oral P021 in Alzheimer’s-model 3xTg-AD mice (Neurobiol Dis 2014) PMID 25046994
  • Bolognin et al., oral P021 and memory decline in 22–24-month-old rats (Neurobiol Aging 2014) PMID 24702821
  • Miller et al., placebo-controlled trial of recombinant CNTF in 570 people with ALS (Ann Neurol 1996) PMID 8967757
  • PubChem CID 56599151 and FDA Global Substance Registration System record UNII VV8CZC8PAS (P021)

For the protocol details

  • ClinicalTrials.gov searches for P021 and P21 (October 8, 2026): no registered trial

For how it works, who should avoid it and the limits of the evidence

  • Baazaoui and Iqbal, review of P021: LIF inhibition, BDNF and GSK-3β (Biomolecules 2022) PMID 36291618
  • Khatoon et al., P021 enters the brain and lowers tau in old rats (J Alzheimers Dis 2015) PMID 26401692
  • Mottolese et al., P021 helped CDKL5-deficient nerve cells in a dish but gave little benefit in mice (J Neurodev Disord 2024) PMID 39592934
  • Falangola et al., P021 in 3xTg-AD mice, with the inventor’s license disclosure (Magn Reson Imaging 2026) PMID 41740658

For uses, the side-effect questions, special situations, trials, identifiers and status outside the US

  • Kazim et al., early P021 treatment in Ts65Dn Down syndrome model mice (Sci Rep 2017) PMID 28368015
  • Liu et al., P021 and retinal changes resembling macular degeneration in old rats and 3xTg-AD mice (Front Aging Neurosci 2019) PMID 31803044
  • Wei et al., P021 from birth in 3xTg-AD mice, body weight unchanged over 120 days (J Alzheimers Dis 2021) PMID 34057082
  • PubChem CID 56599151 and 56589645; FDA GSRS UNII VV8CZC8PAS; ClinicalTrials.gov searches (October 8, 2026)
  • Australian Poisons Standard, October 2026

Doses tagged Community come from public dosing guides and user reports, checked against at least two of them. Those sites aren’t named here because many of them sell peptides or earn commissions on them.